Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man
R. C. Hill,P. Turner +1 more
Reads0
Chats0
TLDR
Preliminary studies in man of a new beta‐adrenoceptive receptor blocking drug, dl‐4‐(2‐hydroxy‐3‐isopropylaminopropoxy)‐indole (LB46), appeared to be of similar potency to propranolol 20 mg in inhibiting isoprenaline‐induced and exercise‐induced tachycardia.Abstract:
1. Preliminary studies in man of a new beta-adrenoceptive receptor blocking drug, DL-4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), are described.
2. LB46, 0·5 mg by oral administration, appeared to be of similar potency to propranolol 20 mg in inhibiting isoprenaline-induced and exercise-induced tachycardia.
3. In comparable beta-receptor blocking doses LB46 did not show the negative chronotropic property possessed by propranolol.read more
Citations
More filters
Journal ArticleDOI
An analysis of skin prick test reactions in 656 asthmatic patients.
TL;DR: Of 656 asthmatic patients referred specifically for allergy assessments, 544 gave positive immediate skin prick tests to at least one of 22 common allergens used routinely, and there was a highly significant association of positive history with positive prick test for all allergens studied.
Journal ArticleDOI
Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
TL;DR: The drug produces smaller decreases in heart rate and cardiac output and alterations in peripheral vascular hemodynamics than beta‐blocking drugs without partial agonist activity, and because of its cardioselectivity, it may be used cautiously in patients with bronchospastic disease.
Journal ArticleDOI
Beta-blockers and plasma renin activity in hypertension.
TL;DR: Observations suggest that the antihypertensive action of propranolol and other β-blockers does not result from their effects on plasma renin activity.
Journal ArticleDOI
Pharmacokinetic Properties of the β-Adrenergic Receptor Blocking Drugs
TL;DR: It is concluded that individual variation in the disposition of these drugs can account, in part, for the wide range in effective dose; but that more information is required on the plasma concentrations associated with therapeutic benefit in the many and diverse conditions for which these drugs are indicated.
Journal ArticleDOI
Pharmacokinetics of pindolol in man
TL;DR: The kinetics of absorption, distribution and excretion of pindolol have been investigated in 17 volunteers after an oral dose or intravenous infusion of 5 mg and they showed up to 4-fold variation after identical doses.
References
More filters